Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Depreciation and Depletion: 2010-2024

Historic Depreciation and Depletion for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $9.5 million.

  • Cytokinetics' Depreciation and Depletion fell 160.85% to -$359,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $1.2 million, marking a year-over-year decrease of 36.84%. This contributed to the annual value of $9.5 million for FY2024, which is 20.17% down from last year.
  • Latest data reveals that Cytokinetics reported Depreciation and Depletion of $9.5 million as of FY2024, which was down 20.17% from $11.9 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Depreciation and Depletion ranged from a high of $11.9 million in FY2023 and a low of $1.8 million during FY2020.
  • Moreover, its 3-year median value for Depreciation and Depletion was $9.5 million (2024), whereas its average is $9.1 million.
  • Per our database at Business Quant, Cytokinetics' Depreciation and Depletion surged by 152.17% in 2022 and then decreased by 20.17% in 2024.
  • Cytokinetics' Depreciation and Depletion (Yearly) stood at $1.8 million in 2020, then increased by 27.78% to $2.3 million in 2021, then skyrocketed by 152.17% to $5.8 million in 2022, then soared by 105.17% to $11.9 million in 2023, then decreased by 20.17% to $9.5 million in 2024.